Accreditation Information

Direct Accreditation:

Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Boston University School of Medicine designates this live activityfor a maximum of 1.5 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Risk Management
This program meets the criteria of the Massachusetts Board of Registration in Medicine for risk management study.


1. Apply current clinical guidelines and up-to-date information to practice.
2. Discuss proper work-up and treatment.
3. Discuss basic aspects of Infectious Diseases

Target Audience

ID Physicians, Fellows, House Staff and Medical Students

Faculty Disclosure

Faculty, Planning Committee, and CME Administrator disclosure statement:

Pranay Sinha, Speaker, has no relevant financial relationships to disclose

Sakina Flint, Program Manager, has no relevant financial relationships to disclose

Tamar barlam, Course Director, has no relevant financial relationships to disclose

Elizabeth Barnett, Planning Committee, receives grant/research support from ABC Company and PaxVax; and has royalties for topics with Elsevier, UpToDate, and BMJ. 

Faculty disclosure of off-label use: 

Faculty members do not plan on discussing unlabeled/investigational uses of a commercial product.

Faculty disclosure policy:

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.